Toxicity and risk factors after combined high-dose-rate brachytherapy and external beam radiation therapy in men ≥75 years with localized prostate cancer

Anastassia Löser(University Hospital Schleswig-Holstein), Rudolf Schwarz(Universität Hamburg), Cedric Oliver Carl(Universität Hamburg), Andreas Krüll(Universität Hamburg), Cordula Petersen(Universität Hamburg), Markus Graefen(Eppendorf (Germany)), Burkhard Beyer(Universität Hamburg), Thorsten Frenzel(Universität Hamburg), Benjamin Löser, Yamini Nagaraj(Universität Hamburg)
Strahlentherapie und Onkologie
November 2, 2018
10.1007/s00066-018-1380-5
Cited by 11

Related Papers

Osteosarcoma Relapse After Combined Modality Therapy: An Analysis of Unselected Patients in the Cooperative Osteosarcoma Study Group (COSS)
|Journal of Clinical Oncology|2005|654
Evaluation of Five Radiation Schedules and Prognostic Factors for Metastatic Spinal Cord Compression
|Journal of Clinical Oncology|2005|347
Osteosarcoma of the Pelvis: Experience of the Cooperative Osteosarcoma Study Group
|Journal of Clinical Oncology|2003|344
Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial
|The Lancet Haematology|2019|329
Second and Subsequent Recurrences of Osteosarcoma: Presentation, Treatment, and Outcomes of 249 Consecutive Cooperative Osteosarcoma Study Group Patients
|Journal of Clinical Oncology|2008|235